Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Anticancer Research · 2023
DOI: 10.21873/anticanres.16550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Gai Yamashita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Nivolumab, Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan isaku@tokyo-med.ac.jp.
Zitieren
APA
Yamashita, G., Okamoto, I., Ito, T., Tokashiki, K., Okada, T., & Tsukahara, K. (2023). Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.16550
Vancouver
Yamashita G, Okamoto I, Ito T, Tokashiki K, Okada T, Tsukahara K. Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Anticancer Research. 2023. doi:10.21873/anticanres.16550
BibTeX
@article{Yamashita2023,
author = {Yamashita, Gai and Okamoto, Isaku and Ito, Tatsuya and Tokashiki, Kunihiko and Okada, Takuro and Tsukahara, Kiyoaki},
title = {Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16550}
}
EUVIMED